05:53 PM EDT, 05/14/2025 (MT Newswires) -- AbCellera Biologics ( ABCL ) said Health Canada authorized its clinical trial application for a phase 1 study of an investigational antibody medicine designed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, known as hot flashes, associated with menopause.

The trial for ABCL635 is expected to begin in Q3 and will evaluate the treatment's safety profile, pharmacokinetics and pharmacodynamics in healthy participants and postmenopausal women with symptoms, the Vancouver-based company said Wednesday in a statement.

The company's shares rose 0.1% in after-hours trading.